Company intelligence / Profile preview

Avivo Biomedical Inc.

Vancouver, British Columbia, Canadax.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company is in preclinical development of its proprietary enzyme system that converts blood type A to type O (universal donor type) for both organ transplantation and blood transfusion applications.

Therapeutic areas: Hematology
Modalities: Enzymatic conversion technology
Industry: Biotech

Drug pipeline

7 assets

A to O Packed RBC Conversion

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Mayo Clinic

Beyond the preview

Go deeper on Avivo Biomedical Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avivo Biomedical Inc..

Explore the full profile